| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $180.9M | +1.2% |
| Cost of Revenue | $53.2M | -10.8% |
| Gross Profit | $127.7M | +7.2% |
| R&D Expense | $46.0M | -7.0% |
| SG&A Expense | $40.8M | -11.2% |
| Operating Income | -$5.0M | +79.4% |
| Pre-tax Income | -$9.0M | +61.9% |
| Income Tax | $3.1M | -60.0% |
| Net Income | -$12.1M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $27.5M | -16.8% |
| Short-term Investments | $24.4M | -49.5% |
| Accounts Receivable | $16.4M | -18.1% |
| Current Assets | $90.7M | -25.4% |
| Total Assets | $164.7M | -9.2% |
| Current Liabilities | $126.5M | +24.4% |
| Long-term Debt | $29.3M | +0.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $14.5M | +18.9% |
| Capital Expenditures | $661K | +26.9% |
| Investing Cash Flow | $9.1M | +172.9% |
| Financing Cash Flow | -$29.7M | -739.0% |
| Free Cash Flow | $13.9M | +18.5% |
| +61.4% |
| EPS (Basic) | -$0.08 | +61.9% |
| EPS (Diluted) | -$0.08 | +61.9% |
| Total Liabilities |
| $158.4M |
| +0.9% |
| Stockholders' Equity | $6.3M | -74.0% |